Feb 12, 2019
Visiongain Report Claims There is Huge Potential Within the $117bn Cancer Immunotherapy Market
Jan 09, 2019
Oncolytic Virus Cancer Therapy Pipeline Insights Report 2018: Some of the Emerging Products include Pexa-Vec of Transgene/SillaJen, Telomelsin of Oncolys, and Canerpaturev (TBI-1401) of Takara Bio
Jan 04, 2019
Candel Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 28, 2018
Targovax is Invited to Present at Upcoming Investor and Industry Conferences
Nov 26, 2018
Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer
Nov 26, 2018
Alcyone Lifesciences Announces the Use of AMC Intratumoral Delivery Platform in the Treatment of First Patient in DNX-2440 Glioblastoma Trial
Nov 19, 2018
ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France
Nov 15, 2018
PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors
Nov 13, 2018
DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer
Nov 07, 2018
Effectiveness of DNAtrix's DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer
Nov 01, 2018
Targovax ASA: Third quarter 2018 Results
Oct 25, 2018
Mitra Biotech Advances Development of Next-Generation Cancer Immunotherapies
Oct 25, 2018
Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses
Oct 18, 2018
Cancer Gene Therapy Market to Reach $2.08 Bn, Globally, by 2023 at 32.4% CAGR, Says Allied Market Research
Oct 11, 2018
Targovax Key Opinion Leader Symposium on Oncolytic Viruses in New York City Today, 11 October, 2018
Sep 27, 2018
Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018
Sep 13, 2018
Spotting the Virus: Russian-Canadian Research Development to Increase the Effectiveness of Viral Cancer Therapy
Sep 13, 2018
EMBL Ventures Portfolio Company, ViraTherapeutics, Acquired by Boehringer Ingelheim in EUR 210 Million (USD 245 Million) Transaction
Sep 13, 2018
EMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 Million (USD 245 Million) Transaction
Sep 12, 2018
Targovax Announces Publication of New Oncolytic Virus Data in the Journal of Medical Virology and Cancer Gene Therapy